ArticleHeart and vessels2009
Interleukin-2 enhances the cytotoxic activity of circulating natural killer cells in patients with chronic heart failure.
Article in Heart and vessels, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The immunology of diabetic cardiomyopathy.Frontiers in endocrinology · 2025Review
- Amino acid and vitamin supplementation improved health conditions in elderly participants.Journal of clinical biochemistry and nutrition · 2012Article
- Ox-LDL can enhance the interaction of mice natural killer cells and dendritic cells via the CD48-2B4 pathway.Heart and vessels · 2011Article
- Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention.Heart and vessels · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our objective was to investigate the effect of interleukin-2 (IL-2) on the cytotoxic activity of natural killer (NK) cells in patients with chronic heart failure (CHF). Natural killer cells were isolated from 48 patients with CHF and 30 healthy subjects. The cytotoxic activities of the NK cells were assessed with the thiazolyl blue tetrazolium bromide (MTT) approach. Interleukin-2 (20 ng/ml) was added to the cell culture to stimulate the cytotoxicity of the NK cells. The cell number in the New York Heart Association (NYHA) class II, III, and IV was 27.9 +/- 2.5, 21.2 +/- 2.7, and 16.8 +/- 2.6 cells/microl, respectively, which was significantly lower than in the control group (31.2 +/- 3.6 cells/microl, all P < 0.01). The cytotoxic activities in NYHA II, III, and IV groups were 28.6% +/- 3.2%, 16.0% +/- 2.2%, and 12.1% +/- 2.9%, respectively, which was lower than in the control group (41.0% +/- 4.0%, all P < 0.01). Univariate analysis showed a close correlation between the NK cell cytotoxicity and the left ventricular ejection fraction (r = 0.949, P < 0.001). After in vitro treatment with IL-2, there was a significant increase in the cytotoxic activity of the NK cells in the control and the three heart failure groups (all P < 0.01). There is a significant reduction in the number and the cytotoxic activity of circulating NK cells in patients with CHF. The degree of NK cell deficiency is closely related to the severity of left ventricular dysfunction. In vitro treatment with IL-2 improves the cytotoxic activity of NK cell from the CHF patients.
Indexed as
Identifiers
19626401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.